Psoriasis Drugs Poised For The Q2 Spotlight
Executive Summary
With Celgene's psoriasis pill Otezla for sale and AbbVie in the midst of launching a new competitor to blockbuster brands like Novartis' Cosentyx and J&J's Tremfya, investors will be focused on the category as drug makers report second quarter financials.
You may also be interested in...
UCB Spotlights Bimekizumab And Other Later-Stage R&D Projects
Belgium-headquartered UCB has a group of antibody-based products in mid to late-stage clinical studies which will be competing in the dermatology/immune disorders marketplace in the next few years.
J&J US Pharma Sales Under Pressure From Pricing And Generics
A 6% negative pricing impact in the US and generic Zytiga were headwinds for Johnson & Johnson's pharmaceutical business in the second quarter.
When It Comes To FTC M&A Review, The Times May Be A Changin'
Spark signaled in an SEC filing that its merger with Roche could be delayed into 2020, fueling more speculation that FTC is increasing scrutiny over biopharma mergers.